Benefits
Stimulant-free metabolism support (human efficacy data limited)
InnoSlim® reduces intestinal glucose absorption (by downregulating SGLT1 glucose transporter) and activates AMPK-driven fat oxidation in adipocytes — acting through cell-culture and animal mechanisms with no stimulant, thyroid, or adrenal activation. The only human data on body weight, body fat, and waist circumference come from a small manufacturer-run trial (n=12) that has not been published in a PubMed-indexed journal, so these reductions are not confirmed by independent research.
Adiponectin elevation and insulin sensitivity
InnoSlim® significantly elevates adiponectin — the key insulin-sensitizing hormone secreted by healthy adipose tissue. Higher adiponectin improves muscle glucose uptake, reduces liver fat, and shifts whole-body metabolism toward fat oxidation rather than fat storage — a metabolic effect shown mainly in cultured cells and in obese mice. Whether adiponectin elevation from InnoSlim® produces meaningful benefits in people has not been demonstrated in a PubMed-indexed trial.
Blood glucose management
By reducing SGLT1-mediated glucose absorption in the intestine and improving peripheral insulin sensitivity through adiponectin elevation, the glucose-lowering effects reported for InnoSlim® come from a small manufacturer trial (n=12) that is not indexed in PubMed and from cell and animal studies; they have not been confirmed in independent human research. In the one indexed human trial of a related herbal formula, fasting and post-meal glucose did not differ significantly from placebo.
Mechanism of action
SGLT1 downregulation and AMPK activation
InnoSlim®'s specific ginsenoside profile (Rb1-dominant) downregulates SGLT1 (sodium-glucose cotransporter 1) in intestinal epithelium — reducing dietary glucose absorption into circulation. The absorbed ginsenosides then activate AMPK (AMP-activated protein kinase) in muscle and adipose tissue, upregulating GLUT4 glucose transporter expression and shifting cellular metabolism toward fat oxidation. Concurrently, InnoSlim® stimulates adiponectin secretion from adipocytes through PPARγ activation — providing a systemic insulin-sensitizing hormone signal that amplifies the direct metabolic effects.
Clinical trials
Human clinical study of InnoSlim® (250 mg/day, a Panax notoginseng + Astragalus membranaceus blend) effects on body weight, body fat, blood glucose, and adiponectin in overweight adults. Note: full peer-reviewed publication for InnoSlim®-specific clinical trials may be limited; primary documentation through NuLiv Science (manufacturer).
Two evidence streams. (1) published toxicology (PMID 31354815): a bacterial reverse-mutation test, an in vivo mouse micronucleus test, and a 28-day repeated-dose oral toxicity study in rats (NOAEL 1200 mg/kg/day). (2) NON-PUBMED efficacy trial: 16-week randomized double-blind crossover trial in 12 healthy adults (Huang 2022, J Biochemistry & Biotechnology — not PubMed-indexed); 5 capsules/day Astragalus + Notoginseng saponins. NCT03654391. Trial cited by NuLiv but full peer-reviewed PubMed publication is pending.
Published (toxicology, PMID 31354815): InnoSlim® showed no mutagenicity and no toxic effects in a 28-day rat study; the NOAEL was the highest dose tested, 1200 mg/kg/day. This is a safety study and did not measure weight loss or glucose control. NON-PUBMED efficacy data (Huang 2022, J Biochem Biotechnol): manufacturer reports ~25% reduction in HOMA-IR (insulin resistance), 20% reduction in blood insulin, 5% reduction in total cholesterol, 8% reduction in LDL and blood glucose, ~30% reduction in triglycerides over 6 weeks. Mechanism: AMPK activation via adiponectin upregulation.